NCT07405164
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07405164
Title Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Acronym MK-6482-043/LITESPARK-043
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.